Bionano Genomics Reports $6.7M Revenue in Q1 2026, Faces Liquidity Challenges

Bionano Genomics, Inc. reported a total revenue of $6.7 million for the first quarter of 2026, reflecting a 4% increase from $6.5 million in the same period of 2025. The growth was primarily driven by a 40% rise in product revenue, which reached $6.1 million, up from $6.0 million year-over-year. This increase was attributed to higher sales of optical genome mapping (OGM) instruments and consumables, despite a significant decline in software revenue, which fell by 40% to $1.2 million. The company recorded a net loss of $8.3 million for the quarter, compared to a loss of $3.1 million in the prior year, resulting in a net loss per share of $0.76, an improvement from $1.15 per share in the previous year.

In terms of operational metrics, Bionano's installed base of OGM systems grew to 399 units, a 5% increase from 379 units a year earlier. The company sold 8,178 flowcells during the quarter, marking a 17% increase from 6,994 flowcells sold in the same period of 2025. However, the company faced challenges in the Asia Pacific region, where geopolitical and macroeconomic factors have led to a slowdown in business, particularly affecting manufacturing partners reliant on government funding.

Bionano's total operating expenses for the quarter were $11.1 million, a slight decrease from $11.4 million in the previous year. Research and development expenses increased by 32% to $3.1 million, driven by higher personnel costs and consulting fees. Selling, general, and administrative expenses decreased by 11% to $8.0 million, reflecting cost-cutting measures implemented in previous years. The company reported cash and cash equivalents of $3.4 million as of March 31, 2026, alongside $11.0 million in short-term investments and $10.3 million in restricted cash.

Looking ahead, Bionano Genomics faces substantial challenges regarding its liquidity and ability to continue as a going concern. The company has indicated that it will need to raise additional capital to fund its operations, as its current cash reserves are insufficient to cover anticipated expenses over the next twelve months. Management is exploring various financing options, including public or private equity and debt financings, but acknowledges the uncertainty surrounding the availability of such funding. The company has also expressed concerns about the potential need to curtail operations or seek bankruptcy protection if it cannot secure the necessary capital in a timely manner.